Evanston, Illinois — A team of Northwestern University scientists has developed the first wireless, implantable temperature sensor to detect inflammatory flareups in patients with Crohn’s disease. The approach offers long-term, real-time monitoring and could enable clinicians to act earlier to prevent or limit the permanent damage caused by inflammatory episodes....
Latest News
CHICAGO, Illinois — A genetic change or variant in a gene called SCN2A is a known cause of infantile seizures, autism spectrum disorder and intellectual disability, as well as a wide range of other moderate-to-profound impairments in mobility, communication, eating and vision. The severity of these disorders can vary widely...
South Bend, Indiana – A groundbreaking neurobiology study has delivered the first direct scientific comparison of the two dominant laboratory models used to study multiple sclerosis (MS), potentially reshaping how future treatments are developed. Published by researchers at University of Notre Dame, the study examined how two widely used experimental...
South Bend, Indiana – Certain types of light have proven to be an effective, minimally invasive treatment for cancers located on or near the skin when combined with a light-activated drug. But deep-seated cancers, surrounded by tissue, blood and bone, have been beyond the reach of light’s therapeutic effects. To...
South Bend, Indiana – Researchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis. The crux of the diagnostic is a biochip that...
South Bend, Indiana – What could cancer teach us about tuberculosis? That’s a question Meenal Datta has been chasing since she was a graduate student. Once the body’s immune system is infected with tuberculosis, it forms granulomas — tight clusters of white blood cells — in an attempt to wall...
Notre Dame’s famous “Touchdown Jesus” mural lit up for Rare Disease Day on Tuesday.
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that results from its Phase 1b/2 clinical trial of NOUS-209 in Lynch Syndrome (LS) carriers have been published in Nature Medicine (D’Alise et...
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognize and eliminate cancer cells before tumors develop Final...
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation off-the-shelf and personalized neoantigen cancer immunotherapies, today announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. Following positive safety and immunogenicity data reported at...